No evident association between efavirenz use and suicidality was identified from a disproportionality analysis using the faers database

Journal of the International AIDS Society

Volumn 17, Issue , 2014, Pages

  Napoli, Andrew A ^a   Wood, Jennifer J ^a   Coumbis, John J ^a   Soitkar, Amit M ^a   Seekins, Daniel W ^a   Tilson, Hugh H ^b  

^a BRISTOL MYERS SQUIBB   (United States)

^b The University of North Carolina at Chapel Hill   (United States)

Author keywords

Antiretroviral; Disproportionality; Efavirenz; Food and drug administration adverse event reporting system; HIV; Multi Item gamma poisson shrinker.; Suicidality

Indexed keywords

ATAZANAVIR; DARUNAVIR; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ETRAVIRINE; FLUOXETINE; NEVIRAPINE; RALTEGRAVIR; SERTRALINE; ANTIRETROVIRUS AGENT; BENZOXAZINE DERIVATIVE;

ANALYTIC METHOD; ARTICLE; BAYES THEOREM; COMPLETED SUICIDE; DRUG USE; EMPIRICAL RESEARCH; GEOMETRY; HUMAN; MAJOR CLINICAL STUDY; MEDICAL DICTIONARY FOR REGULATORY ACTIVITIES; MONOTHERAPY; MULTI ITEM GAMMA POISSON SHRINKER; MYOPATHY; RETROSPECTIVE STUDY; RHABDOMYOLYSIS; SUICIDAL IDEATION; SUICIDE; SUICIDE ATTEMPT; EPIDEMIOLOGY; HIV INFECTIONS; PATHOPHYSIOLOGY; POSTMARKETING SURVEILLANCE; STATISTICS AND NUMERICAL DATA; UNITED STATES;

ANTI-RETROVIRAL AGENTS; BENZOXAZINES; HIV INFECTIONS; HUMANS; PRODUCT SURVEILLANCE, POSTMARKETING; SUICIDE; UNITED STATES;

EID: 84907653017     PISSN: None     EISSN: 17582652     Source Type: Journal    
DOI: 10.7448/IAS.17.1.19214     Document Type: Article

References (23)

1. Bristol-Myers Squibb. Sustiva (efavirenz) Package Insert. 2014 [cited 2014 Jun 1]. Available from: http://packageinserts.bms.com/pi/pi-sustiva.pdf
2. Clifford DB, Evans S, Yang Y, Acosta EP, Goodkin K, Tashima K, et al. Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals. Ann Intern Med. 2005; 143(10):714-21.
3. Hawkins T, Geist C, Young B, Giblin A, Mercier RC, Thornton K, et al. Comparison of neuropsychiatrie side effects in an observational cohort of efavirenz- and protease inhibitor-treated patients. HIV Clin Trials. 2005; 6(4):187-96. doi: 10.1310/92VR-FP24-J8GA-B49Q.
4. Lochet P, Peyriere H, Lotthe A, Mauboussin JM, Delmas B, Reynes J. Long-term assessment of neuropsychiatric adverse reactions associated with efavirenz. HIV Med. 2003;4(1):62-6.
5. Mollan KR, Smurzynski M, Eron JJ, Daar ES, Campbell TB, Sax PE, et al. Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data. Ann Intern Med. 2014;161(1):1-10.
6. FDA Adverse Event Reporting System (FAERS). 2012 [cited 2014 Mar 3]. Available from: http://www.fda.gov/Drugs/GuidanceComplianceRegulatorylnformation/Surveillance/AdverseDrugEffects/default.htm
7. Ben-Hamou M, Marshall NS, Grunstein RR, Saini B, Fois RA. Spontaneous adverse event reports associated with zolpidem in Australia 2001-2008. J Sleep Res. 2011;20(4):559-68. doi: 10.1111/j.1365-2869.2011.00919.x.
8. Salvo F, Polimeni G, Moretti U, Conforti A, Leone R, Leoni O, et al. Adverse drug reactions related to amoxicillin alone and in association with clavulanic acid: data from spontaneous reporting in Italy. J Antimicrob Chemother. 2007;60(l):121-6. doi: 10.1093/jac/dkm111.
9. Zink RC, Huang Q, Zhang LY, Bao WJ. Statistical and graphical approaches for disproportionality analysis of spontaneously-reported adverse events in pharmacovigilance. Chin J Nat Med. 2013;11(3):314-20. doi: 10.1016/S1875-5364(13)60035-7.
10. Sakaeda T, Tamon A, Kadoyama K, Okuno Y. Data mining of the public version of the FDA Adverse Event Reporting System. Int J Med Sci. 2013;10(7):796-803. doi: 10.7150/ijms.6048.
11. Suling M, Pigeot l. Signal detection and monitoring based on longitudinal healthcare data. Pharmaceutics. 2012;4:607-40.
12. Stone M, Laughren T, Jones ML, Levenson M, Holland PC, Hughes A, et al. Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration. BMJ. 2009;339:b2880. doi: 10.1136/bmj.b2880.
13. Merck Sharp & Dohme. Raltegravir prescribing information. 2013 [cited 2014 Mar 3]. Available from: http://www.merck.eom/product/usa/pi-circulars/i/isentress/isentress-pi.pdf
14. Council for International Organizations of Medical Sciences (CIOMS) Working Group IV. Benefit-risk balance for marketed drugs: evaluating safety signals. Geneva: CIOMS; 1998.
15. Dohme MS. Raltegravir summary of product characteristics [Internet]. 2013 [cited 2014 Mar 3]. Available from: http://www.medicines.org.uk/emc/medicine/20484
16. Szarfman A, Machado SG, ONeill RT. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDAs spontaneous reports database. Drug Saf. 2002;25(6):381-92.
17. Szarfman A, Tonning JM, Doraiswamy PM. Pharmacovigilance in the 21st century: new systematic tools for an old problem. Pharmacotherapy. 2004; 24(9):1099-104.
18. Brown P, Faloon L. The incidence and reporting of adverse drug reactions in the Division of Psychiatry. Pharm World Sci. 2001;23(5):181-2.
19. Lyness JM, Cox C, Curry J, Conwell Y, King DA, Caine ED. Older age and the underreporting of depressive symptoms. J Am Geriatr Soc. 1995;43(3):216-21.
20. U.S. Preventive Services Task Force. Screening for depression in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2002;151(11):784-93.
21. UK National Screening Committee. The UK NSC policy on depression screening in adults. 2013 [cited 2014 Mar 3]. Available from: http://www.screening.nhs.uk/depression
22. Pariente A, Gregoire F, Fourrier-Reglat A, Haramburu F, Moore N. Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias. Drug Saf. 2007;30(10):891-8.
23. Chippindale S, French L. HIV counselling and the psychosocial management of patients with HIV or AIDS. BMJ. 2001;322(7301):1533-5.